Insider Analysis From Kantar Health China On The Implications Of China’s New EDL For Pharma
This article was originally published in PharmAsia News
Executive Summary
China’s Ministry of Health issued the new Essential Drug List on March 15, which significantly broadens coverage and now includes many best-selling products from multinational companies. This update will have serious implications for multinational pharmaceutical corporations operating in China.
You may also be interested in...
Insider Analysis From Kantar Health On Improving Compliance In China’s Diabetes Patients
China is expected to see the level of diabetes among its population rise by nearly two-thirds over the next few decades, and the majority of Chinese patients do not take their medication as directed. Pharma companies can help educate consumers to improve compliance and better manage the disease.